Center for Cancer Vaccines Team
Our Staff
Director
Patrick Ott, MD, PhD, Clinical Director of Center for Immuno-oncology; IND holder of NeoVax; Associate Professor of Medicine, Harvard Medical School
Advisors
Catherine J. Wu, MD, Chief, Division of Stem Cell Transplantation and Cellular Therapies; Professor of Medicine, Harvard Medical School; Faculty Advisor for Translational Immunogenomics Lab
Ed Fritsch, PhD, Presidential Scholar
Principal Investigators
Toni Choueiri, MD, Renal Cell Carcinoma
Matthew Davids, MD, MMSc, and Inhye Ahn, MD, Chronic Lymphocytic Leukemia
Panagiotis (Panos) Konstantinopoulos, MD, PhD, Ovarian Cancer
Reid Merryman, MD, Follicular Lymphoma
Patrick Ott, MD, PhD, Melanoma
David Reardon, MD, and Bryan Iorgulescu, MD, MPH, Glioblastoma
Clinical and Research Management
Cleo Forman, Computational Biologist
Haley Greenslade, Research Project Manager
Derin Keskin, Immunologist
Oriol Olive Noguer, Senior Clinical Trials Manager
Chloe Tu, Computational Biologist
Other Collaborators
Broad Clinical Labs
Broad Institute Proteomics Platform
Broad Translational Analysis Group (TAG Team)
Hacohen Lab, Broad Institute
Translational Immunogenomics Laboratory (TIGL)
Our Experts in the News
- Cathy Wu named to The Fierce 50 for her cancer research that’s driving meaningful change.
- Cathy Wu and Patrick Ott identified as key scientists making cancer vaccines happen by STAT
- Cathy Wu speaks to The Harvard Gazette about progress in personalized cancer vaccines
- Cathy Wu interviewed by CNN for: The doctor behind the next big thing in cancer treatment
- Cathy Wu wins prestigious Sjöberg Prize for cancer vaccine research
- Toni Choueiri, Cathy Wu, and David Braun join the U.S. Department of Defense's new Academy of Kidney Cancer Investigators that will help advance kidney cancer research to understand resistance and develop new treatments that harness the immune system
- DFCI-Broad collaboration to improve neoantigen prediction: New tool could help researchers design better cancer vaccines
- NeoVax RCC clinical trial commences: Personalized vaccine to be tested with for patients with kidney cancer
- David Reardon's GBM NeoVax study published in Nature: Personal neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial, new study shows
- NeoVax featured in Harvard Magazine issue on Precision Medicine
- Parker Institute for Cancer Immunotherapy Q&A with Cathy Wu
- Cathy Wu interviewed on WBUR's "This Moment in Cancer" special series
- Cathy Wu named one of "Nine Innovators to Watch in 2018" by Smithsonian Magazine
- Cathy Wu featured on Novel Targets podcast, "Cancer Vaccine Renaissance"
- Cathy Wu one of four Dana-Farber researchers joining the Parker Institute for Cancer Immunotherapy
- Cathy Wu and Patrick Ott publish first in-human study using a peptide-based neoantigen vaccine: Personal neoantigen vaccine prompts strong anti-tumor response in patients, new study shows